BioCentury
ARTICLE | Company News

Woodford mum on his GSK wish list

October 27, 2015 12:02 AM UTC

Woodford Investment Management and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to comment on media reports that fund manager Neil Woodford asked GSK Chairman Philip Hampton to explore the separation of the company's HIV business ViiV Healthcare, its consumer healthcare business and its Stiefel dermatology business from its core medicines and vaccines business. Woodford declined to disclose whether it holds a stake in GSK.

ViiV is GSK's HIV-focused joint venture with Pfizer Inc. (NYSE:PFE) and Shionogi & Co. Ltd. (Tokyo:4507). In May, GSK opted to retain its stake in ViiV after considering a spin-off via an IPO (see BioCentury Extra, May 6). ...